Giacomo Bastianelli - CEO, SCI-BRAIN

Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app

Network Power<100 people

Roles

🔥50%

Startup Founder

💸50%

Marketing

✔️50%

Geos

🇷🇺50%

Russia

🇫🇷25%

France

🇿🇦25%

South Africa

Work Background

MeiogenixCo-Founder

Mar. 2020 - Mar. 2022Paris, Ile-de-France, France

Marie Curie NetworksLecturer in Entrepreneurship

Apr. 2018 - Oct. 2018Entrepreneurship course: from an idea/discovery to a startup. Tools and tricks for a successful entrepreneurial journey. Marie Curie Networks: PHA-ST-TRAIN-VAC, GLYCOVAX

LounjeeCo-Founder

Jun. 2017Paris Area, FranceBuilding vertical networks

PROG VENTURESOwner

Jan. 2017Paris Area, FrancePersonal investment and consulting company

SCI-BRAINCo-Founder

Jan. 2017Tallinn, EstoniaSCI-BRAIN is a SaaS platform to map and identify experts in any topic. Helping companies to access the expertise they need to grow their business.

BliNK TherapeuticsCEO

Dec. 2014 - Dec. 2015Stevenage, United KingdomBliNK Therapeutics is a biotechnology company dedicated to the development of innovative biotherapeutics for life threatening diseases such as cancer. BliNK's technologies were invented and developed in the labs of Facundo Batista (CRICK Institute, London) and Vincenzo Cerundolo (University of Oxford). I was appointed as CEO during the the M&A with the antibody team and technologies of Valneva. Responsibilities: - Manage the transition during the M&A process - Supervise R&D activities and technology development - Company management and reporting - Supervise IP portfolio and strategy Achievements: - Successfully led the transition after the M&A - Established operational processes between the two sites (Stevenage UK, Lyon France) - Set-up target scouting process

Key NeurosciencesBoard member

Nov. 2012 - Jan. 2016Paris Area, FranceParticipate in key decisions for the company.

TravellutionCo-founder & CEO

Mar. 2011 - Jun. 2014Paris Area, FranceTravellution is a web platform to help travelers and groups to conceive and plan a detailed trip. Responsibilities: - Company management & reporting - Oversee product development with technical team - Define strategic marketing actions (online/offline) Achievements: - Raised €300K from business angels - Grew engagement - Obtained €100K grant for technology development

Key NeurosciencesCEO

Jan. 2011 - Oct. 2012Paris Area, FranceKey Neurosciences is a venture-incubator company acting as an integrator and catalyzer of the most promising neurosciences opportunities. Responsibilities: - Structure the process of company inception - Lead operations on neurosciences projects - Fully managed the company - Reporting to board and investors Achievements: - Raised $1M - Expand IP company's portoflio - In-licensing deals on projects to accelerate/fund - Elaborate the venture-incubator business model

Kurma PartnersAdvisor

Jan. 2011Paris Area, France

University of BolognaGuest Lecturer

Jan. 2011 - Jan. 2012Bologna Area, ItalyThe School of Biotechnology of the University of Bologna is the highest-ranked M.S. in Biotechnology in Italy. - Lectures in technology entrepreneurship at the School of Biotechnology, University of Bologna.

MeiogenixCo-Founder & CEO

Nov. 2010 - Mar. 2020Paris Area, FranceMeiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps developing new products to address global food and industrial challenges. Responsibilities: - Company management - Lead and supervise R&D activities - Coordinate business operations - Define the intellectual property strategy Achievements: - Established deals with large industrial players such as Bayer (https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Meiogenix-collaborate-accelerate-agricultural-innovation-through-development-unique) - Raised $3M from VC - Contributed to the conception of new technologies - In-licensed technologies from academia and out-licensed to industry - Successful personal exit